Literature DB >> 3939491

Maternal epilepsy and birth defects: a case-control study in the Italian Multicentric Registry of Birth Defects (IPIMC).

R Bertollini, P Mastroiacovo, G Segni.   

Abstract

A case control study on the association between maternal epilepsy, anticonvulsants use during pregnancy and birth defects was carried out in the Italian Multicentric Registry of Birth Defects (IPIMC). In the period 1980-1983, 7,607 malformed babies out of 439,717 total births (still + live) were registered. Fourty-one malformed babies with maternal epilepsy were identified (5.39 X 1,000). The overall relative risk of having a malformed baby among pregnant epileptic women was 1.87. Spina Bifida, Congenital Heart Defects, Clefts, Diaphragmatic Hernia and Trisomy 18 were more frequent than expected among babies with maternal epilepsy. The different therapeutic regimens were also tested to identify the possible independent teratogenic effect of anticonvulsants. A statistically significant association between Spina Bifida and Valproic Acid (odds ratio 22.7; Fisher p value = 0.0364) was observed: no other anticonvulsant tested showed any association with any type of malformation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3939491     DOI: 10.1007/bf00162315

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  21 in total

1.  [ARE ANTI-EPILEPTIC DRUGS HARMFUL DURING PREGNANCY?].

Authors:  D JANZ; U FUCHS
Journal:  Dtsch Med Wochenschr       Date:  1964-02-07       Impact factor: 0.628

2.  Teratogenic effect of anticonvulsants.

Authors:  J South
Journal:  Lancet       Date:  1972-11-25       Impact factor: 79.321

3.  The course and outcome of pregnancy in women with epilepsy.

Authors:  T Bjerkedal; S L Bahna
Journal:  Acta Obstet Gynecol Scand       Date:  1973       Impact factor: 3.636

4.  Sodium valproate and neural tube defects.

Authors: 
Journal:  Lancet       Date:  1982-12-04       Impact factor: 79.321

5.  Valproic acid and spina bifida.

Authors:  T Bjerkedal; A Czeizel; J Goujard; B Kallen; P Mastroiacova; N Nevin; G Oakley; E Robert
Journal:  Lancet       Date:  1982-11-13       Impact factor: 79.321

6.  Fetal head growth retardation associated with maternal antiepileptic drugs.

Authors:  V K Hiilesmaa; K Teramo; M L Granström; A H Bardy
Journal:  Lancet       Date:  1981-07-25       Impact factor: 79.321

7.  [Congenital abnormalities, cleft lip and cleft palate in particular, in children of epileptic mothers].

Authors:  J Elshove; J H van Eck
Journal:  Ned Tijdschr Geneeskd       Date:  1971-08-14

8.  Possible teratogenicity of valproic acid.

Authors:  M R Gomez
Journal:  J Pediatr       Date:  1981-03       Impact factor: 4.406

9.  Anticonvulsants and parental epilepsy in the development of birth defects.

Authors:  S Shapiro; S C Hartz; V Siskind; A A Mitchell; D Slone; L Rosenberg; R R Monson; O P Heinonen
Journal:  Lancet       Date:  1976-02-07       Impact factor: 79.321

10.  Congenital malformations among infants born to epileptic women.

Authors:  C R Lowe
Journal:  Lancet       Date:  1973-01-06       Impact factor: 79.321

View more
  12 in total

1.  Congenital cardiac anomalies relative to selected maternal exposures and conditions during early pregnancy.

Authors:  G M Shaw; L H Malcoe; S H Swan; S K Cummins; J Schulman
Journal:  Eur J Epidemiol       Date:  1992-09       Impact factor: 8.082

2.  Teratogenic effect of carbamazepine.

Authors:  V Vestermark; S Vestermark
Journal:  Arch Dis Child       Date:  1991-05       Impact factor: 3.791

Review 3.  Getting to the heart of the matter: epidemiology of cyanotic heart defects.

Authors:  Jennifer L Kornosky; Hamisu M Salihu
Journal:  Pediatr Cardiol       Date:  2008-01-10       Impact factor: 1.655

4.  Autosomal dominant nonsyndromic cleft lip and palate: significant evidence of linkage at 18q21.1.

Authors:  Soraya Beiraghi; Swapan K Nath; Matthew Gaines; Desh D Mandhyan; David Hutchings; Uppala Ratnamala; Ken McElreavey; Lucia Bartoloni; Gregory S Antonarakis; Stylianos E Antonarakis; Uppala Radhakrishna
Journal:  Am J Hum Genet       Date:  2007-05-18       Impact factor: 11.025

5.  The frequency of neonatal morbidity after exposure to antiepileptic drugs in utero: a retrospective population-based study.

Authors:  Silva Burja; Zlatka Rakovec-Felser; Milena Treiber; Dusanka Hajdinjak; Marijana Gajsek-Marchetti
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

6.  Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy.

Authors:  A Ornoy; E Cohen
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

Review 7.  Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children.

Authors:  Zixuan Wang; Phoebe W H Ho; Michael T H Choy; Ian C K Wong; Ruth Brauer; Kenneth K C Man
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

8.  Anticonvulsant drugs and malformations is there a drug specificity?

Authors:  B Källén; E Robert; P Mastroiacovo; M L Martínez-Frías; E E Castilla; G Cocchi
Journal:  Eur J Epidemiol       Date:  1989-03       Impact factor: 8.082

Review 9.  Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?

Authors:  Page B Pennell
Journal:  Epilepsia       Date:  2008-12       Impact factor: 5.864

Review 10.  Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.

Authors:  C L Harden; K J Meador; P B Pennell; W A Hauser; G S Gronseth; J A French; S Wiebe; D Thurman; B S Koppel; P W Kaplan; J N Robinson; J Hopp; T Y Ting; B Gidal; C A Hovinga; A N Wilner; B Vazquez; L Holmes; A Krumholz; R Finnell; D Hirtz; C Le Guen
Journal:  Neurology       Date:  2009-04-27       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.